Prolight receives first order of approximately SEK 19.9 million from BRAINBox

Prolight Diagnostics AB (publ) today announces that the company has received its first purchase order from BRAINBox Solutions under the supply agreement announced in September 2026. The order value amounts to approximately SEK 19.9 million and covers commercial products ahead of BRAINBox’s planned US launch in traumatic brain injury (TBI).

The order covers commercial products for BRAINBox’s diagnostic and prognostic solution for TBI, which incorporates Prolight’s point-of-care platform Psyros^®.

“This first order under our supply agreement is an important milestone for Prolight. It confirms BRAINBox’s commitment to the launch and marks our transition from development work to commercial readiness,” said Ulf Bladin, CEO of Prolight Diagnostics.

Both companies expect demand for instruments and cartridges to grow as commercialization progresses.

About Us
Prolight Diagnostics develops Psyros^®, a groundbreaking Point-of-Care platform for highly sensitive biomarker diagnostics. By delivering reliable test results in ten minutes or less, Psyros has the potential to revolutionize clinical workflows, improve patient outcomes, and reduce healthcare costs. The platform is initially being developed for areas with significant unmet medical needs such as cardiovascular and neurological conditions and possesses broad potential for a wide range of clinical applications.

The company’s share is traded on the NGM Growth Market marketplace, under the ticker PRLD.

Prolight receives first order of approximately SEK 19.9 million from BRAINBox